Building on the positive data results from the HOPE-2 study, Capricor Therapeutics has announced the commencement of dosing in the HOPE-3 study. This is a Phase 3 clinical trial investigating CAP-1002, a cell therapy for treating late-stage Duchenne muscular dystrophy (DMD).

“We are delighted to begin dosing patients in HOPE-3. The data from our Phase 2 clinical trial suggest that CAP-1002 can slow loss of function by as much as 70% in terms of upper limb skeletal muscle function. Since there are very limited therapeutic options for these patients and CAP-1002 has been shown to be safe and effective, we are pleased to begin this pivotal trial with the goal of achieving regulatory approval as quickly as possible.”

Linda Marbán, Ph.D., CEO of Capricor

HOPE-3 is a randomized, double-blind, placebo-controlled study designed to enroll approximately 70 patients in the United States. Currently, there are no plans to bring the trial to Canada, but we will continue to monitor the progress and share it with our Duchenne community.